CoChat

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors

Open access
Sharma, Madhav D., Rodriguez, Paulo C., Koehn, Brent H., Baban, Babak, Cui, Yan, Guo, Gang, Shimoda, Michiko, Pacholczyk, Rafal, Shi, Huidong, Lee, Eun-Joon, Xu, Hongyan, Johnson, Theodore S., He, Yukai, Mergoub, Taha, Venable, Christopher, Bronte, Vincenzo, Wolchok, Jedd D., Blazar, Bruce R., Munn, David H. · 2018 · Immunity
Cited by 119

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Summary CD103+ dendritic cells are critical for cross‐presentation of tumor antigens. Here we have shown that during immunotherapy, large numbers of cells expressing CD103 arose in murine tumors via direct differentiation of Ly6c+ monocytic precursors. These Ly6c+CD103+ cells could derive from bone‐marrow monocytic progenitors (cMoPs) or from peripheral cells present within the myeloid‐derived suppressor cell (MDSC) population. Differentiation was controlled by inflammation‐induced activation of the transcription factor p53, which drove upregulation of Batf3 and acquisition of the Ly6c+CD103+ phenotype. Mice with a targeted deletion of p53 in myeloid cells selectively lost the Ly6c+CD103+ population and became unable to respond to multiple forms of immunotherapy and immunogenic chemotherapy. Conversely, increasing p53 expression using a p53‐agonist drug caused a sustained increase in Ly6c+CD103+ cells in tumors during immunotherapy, which markedly enhanced the efficacy and duration of response. Thus, p53‐driven differentiation of Ly6c+CD103+ monocytic cells represents a potent and previously unrecognized target for immunotherapy. Graphical Abstract Figure. No Caption available. HighlightsDuring tumor immunotherapy, CD103+ APCs can arise from the myeloid lineageThese CD11c+CD103+ APCs are Batf3 dependent but co‐express monocytic markersDifferentiation of these cells from immature MDSC precursors is controlled by p53Selective ablation of this population results in profound defects in tumor immunity &NA; Conventional CD103+ DCs are critical APCs for cross‐presentation of tumor antigens. Sharma and colleagues show that a potent population of Batf3‐dependent, CD103+ cross‐presenting APCs can arise during tumor immunotherapy via direct differentiation of immature monocytic precursors present in the peripheral MDSC pool.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2017.12.014

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 119

Metadata

Authors
Sharma, M. D., Rodriguez, P. C., Koehn, B. H., Baban, B., Cui, Y., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., Xu, H., Johnson, T. S., He, Y., Mergoub, T., Venable, C., Bronte, V., Wolchok, J. D., Blazar, B. R., & Munn, D. H.
Venue
Immunity
Publisher
Elsevier BV
Published
2018-01
Volume
48
Issue
1
Pages
91-106.e6
ISSN
1074-7613 (ISSN-L)
OpenAlex
W2783617985
Cited by
119
References
11
FWCI
4.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. https://app.cochat.ai/papers/10.1016/j.immuni.2017.12.014
The paper
Sharma, M. D., Rodriguez, P. C., Koehn, B. H., Baban, B., Cui, Y., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., Xu, H., Johnson, T. S., He, Y., Mergoub, T., Venable, C., Bronte, V., Wolchok, J. D., Blazar, B. R., & Munn, D. H. (2018). Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity. https://doi.org/10.1016/j.immuni.2017.12.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.